This content is from:xinyabo体育
Acting Up
ValueAct’s Jeffrey Ubben shows that activist investors needn’t be loud and annoying to be effective.
By Irwin Speizer Jeffrey Ubben: Value stocks plus activism is the strategy (Photographs by Thomas Borening) When ValueAct Capital, an $8 billion hedge fund firm in San Francisco, went scouting for investment targets a few years ago, it spotted Valeant Pharmaceuticals International, a Montreal-based drugmaker. Valeant looked like an underappreciated
To continue reading,subscribe nowto Premium Journalism. Already a subscriber?Login.